Skip to main content
Category

News

NeuroAiD at ASEAN Neurological Association

By News

Moleac will attend the 12th Biennial Convention of ASEAN Neurological Association (ASNA) & 39th Annual Convention of Philippine Neurological Association (PNA), in Manila, Philippines from 21 to 24 November.

Prof. N Venketasubramanian (Ramani) from Singapore, one of the principal investigators of NeuroAiD’s landmark study, CHIMES-E, will present the following posters:

  • Synergistic Effect of Combining MLC601 and Rehabilitation on Post-Stroke Recovery – The CHIMES Study.
  • Targeting Stroke Patients with a Higher Potential of Long-term Benefit from Treatment: Insights from the CHIMES-E Study.
  • Comparison of Long-term Spontaneous Functional Recovery and Response to Treatment with MLC601 between Cortical and Non-cortical strokes – The CHIMES-E Study.

In addition, Moleac and E*Chimes (distributor of NeuroAiD in the Philippines) will host a Twilight symposium with renowned speaker Prof. Simeon Marasigan from the Philippines to introduce the NEURITES study on 22nd November, 17:00 – 19:00:

  • NEURoaid II (MLC901) Assessment in Cognitivitely Impaired Not Demented Subjects: A Pilot Double Blind, Placebo Controlled Randomized Trial in Efficacy and Safety (NEURITES) Study (Preliminary Report).

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

NeuroAiD at Asia Pacific Stroke Conference

By News

Renowned clinicians and researchers will present abstracts from the latest studies conducted on NeuroAiD, including the principal investigators of NeuroAiD’s landmark study, CHIMES-E, demonstrating the long-term benefits of a 3-month course in achieving functional independence:

  • Prof. Christopher Chen from Singapore:

Abstract: Comparison of Long-term Spontaneous Functional Recovery and Response to Treatment with MLC601 between Cortical and Non-cortical strokes – The CHIMES-E Study.

  • Prof. N Venketasubramanian (Ramani) from Singapore

Abstract: Targeting Stroke Patients with a Higher Potential of Long-term Benefit from Treatment: Insights from the CHIMES-E Study.

  • Prof. Nijasri Suwanwela from Singapore

Abstract: Synergistic Effect of Combining MLC601 and Rehabilitation on Post-Stroke Recovery – The CHIMES Study.

Refer to the APSC program for more details – 26th to 28th October, Nanjing, China.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

NeuroAiD at World Congress of Neurology

By News

Moleac’s flagship product, NeuroAiD, will be presented at the 23rd Word Congress of Neurology during oral abstract presentations by A/Prof. Alice Theadom from New-Zealand.

    • A Randomized, Placebo-controlled Pilot Trial to Investigate the Safety and Efficacy of MLC901 (NeuroAiDIITM) in Adults Following Mild or Moderate Traumatic Brain Injury – 19th September, 11:40 – 11:50.

In addition, Moleac will be hosting a symposium on the 17th September with renowned researchers in the field of neurology, to cover the following topics:

    • Prof. Jose Navarro from the Philippines, one of the principal investigators of NeuroAiD’s landmark studies, CHIMES and CHIMES-E, will present NeuroAiD’s long-term benefits in post-stroke recovery and the latest analyses conducted on prognostic factors or poorer outcomes.
    • Prof. Marasigan from the Philippines, will introduce NEURITES, ongoing clinical trial on NeuroAiD in vascular cognitive impairments.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

NeuroAiD presentations at European Stroke Conference

By News

NeuroAiD, Moleac’s main product, will be presented at the 26th European Stroke Conference on 24th May during abstract presentations on the 24th and 26th May by A/Prof. Narayanaswamy Venketasubrmanian:

  • Comparison of Long-term Spontaneous Functional Recovery and Response to Treatment with MLC601 between Cortical and Non-cortical strokes – The CHIMES-E study (24th May)
  • Targeting Stroke Patients with a Higher Potential of Long-term Benefit from Treatment: Insights from the CHIMES-E Study (26th May)
  • Synergistic Effect of Combining MLC601 and Rehabilitation on Post-stroke Recovery – The CHIMES Study (26th May)

In addition, Moleac will be hosting an evening symposium on the 25th May with recognised leaders in the field of stroke and pre-clinical research, to cover the following topics:

  • Prof. Tatjana Rundek from the Unites States will present her work on long-term prognosis and outcome of patients after stroke.
  • Prof. Michel Lazdunski from France, who has conducted several important preclinical studies on NeuroAiD with his team, will present neurorestorative strategies from natural substances.
  • Prof. N Venketasubramanian (Ramani) from Singapore, one of the principal investigators of NeuroAiD’s landmark studies, will present CHIMES and CHIMES-E key outcomes NeuroAiD clinical benefit on post-stroke recovery and insights regarding patients’ selection for clinical research.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

NeuroAiD presentations at European Stroke Organisation Conference

By News

NeuroAiD, Moleac’s main product, will be presented at the 3rd European Stroke Organisation Conference on 16th May during the following poster presentations:

  • Synergistic Effect of Combining MLC601 and Rehabilitation on Post-stroke Recovery – The CHIMES Study
  • Targeting Stroke Patients with a Higher Potential of Long-term Benefit from Treatment: Insights from the CHIMES-E Study

NeuroAid data will also be presented during an abstract presentation on the 18th May by Prof. Christopher Chen, National University of Singapore:

  • Comparison of Long-term Spontaneous Functional Recovery and Response to Treatment with MLC601 between Cortical and Non-cortical strokes – The CHIMES-E study

In addition, Moleac will be hosting an evening symposium on the 16th May with world-class leaders in stroke research, to cover the following topics:

  • Prof. Pamela Duncan from the United States will present her extensive research on capturing outcomes after stroke.
  • Prof. Christopher Chen from Singapore, one of the principal investigators of NeuroAiD’s landmark studies CHIMES and CHIMES-E studies, will present the long term benefits of NeuroAiD on post-stroke recovery.
  • Dr. Boutarene and Dr. Bouabdallah from Algeria will present the observational study they conducted on NeuroAiD with NeST Registry.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

Launch of NeuroAiD in Nigeria

By News

Helping patients reconnect with their lives remain our focus. This February, NeuroAiD will be launched in Nigeria in association with our local distributor, Bolar Pharmaceuticals. Nigeria is one of the most populous nations in Africa, and has recently faced an increasing prevalence of stroke (>250,000 in 2015*) and other cardiovascular diseases. NeuroAiD is bringing a unique evidence-based therapeutic opportunity for the victims to recover faster and better.

*Global Burden Disease 2015 data

Moleac awarded prize from Creative France – recognising the success of French entrepreneurs in Singapore

By News

“Entrepreneur” is a French invention for risk takers committed to innovate, and Moleac is a complete illustration of successful entrepreneurial biopharmaceutical company in Singapore.

A quote from his Excellency, Ambassador Benjamin Dubertret, French Ambassador in Singapore

“The “Creative Next” contest aims at showcasing French ingenuity and identifying inspirational French entrepreneurs or SMEs that have demonstrated creativity and innovation in their business. Thanks to its innovative therapeutic solutions to neurological diseases, finalist company Moleac perfectly embodies the essence of French “creativité”: an exceptional ability to innovate paired with scientific excellence and talent.”

In 2016, Moleac celebrated the 10 years’ anniversary of its flagship product, NeuroAiD.

NeuroAiD was initially launched in Singapore in 2006 and rapidly expended to over 35 countries worldwide. This innovative product fulfills a major therapeutic gap for stroke victims in their journey to recover their functional independence. Today, NeuroAiD is in the running to become Singapore’s first home-grown drug.

The idea was born in France and initially funded from Europe. We saw the opportunity to bridge the gap between Traditional Chinese Medicine (TCM) and Western medicine, two paths which usually don’t cross at all. The decision to locate the company in Singapore was based on the understanding of both Eastern and Western medicine here in Singapore, which is essential for NeuroAiD’s development. We also wanted to ensure our research and data could stand the scrutiny of clinicians internationally. In the past 10 years, NeuroAiD has undergone clinical trials in Singapore and internationally, demonstrating its efficacy in boosting recovery of neurological functions after a stroke. NeuroAiD has reached 20,000 patients last year and we are currently working towards obtaining full-fledged drug approval in the United States and Europe.

We are honored to receive this award from Creative France which represents wider recognition of our commitment to innovate and bring therapeutic solutions to thousands of stroke victims worldwide.

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study

By News

Cerebrovasc Dis 2017; 43:36-42

Published by S. Karger AG, Basel

This analysis from the CHIMES-E study shows that subjects with prognostic factors of poorer outcome get a higher benefit on post-stroke functional recovery with a 3-month course of NeuroAiD compared to placebo, with statistically significant differences seen as early as 3 months and persisting over the long term. At 12 months NeuroAiD almost doubles the chances of achieving functional independence. These results indicate that selection of subjects with poorer prognosis, particularly those with more severe NIHSS score and longer OTT* delay, as well as a longer follow-up period and treatment duration can maximize the recovery potential of subjects included in post-acute stroke clinical trials.

Authors: Narayanaswamy Venketasubramanian, Chun Fan Lee, Sherry H. Young, San San Tay, Thirugnanam Umapathi, Annabelle Y. Lao, Herminigildo H. Gan, Alejandro C. Baroque II, Jose C. Navarro, Hui Meng Chang, Joel M. Advincula, Sombat Muengtaweepongsa, Bernard P.L. Chan, Carlos L. Chua, Nirmala Wijekoon, H. Asita de Silva, John Harold B. Hiyadan, Nijasri C. Suwanwela, K.S. Lawrence Wong, Niphon Poungvarin, Gaik Bee Eow, Christopher L.H. Chen for the CHIMES-E Study Investigators

Keywords: Acute stroke, Stroke recovery, MLC601, NeuroAiD, Prognosis, Clinical trial, Long-term outcome

Abstract:

Background: The Chinese Medicine NeuroAiD Efficacy on Stroke recovery – Extension (CHIMES-E) study is among the few acute stroke trials with long-term outcome data. We aimed to evaluate the recovery pattern and the influence of prognostic factors on treatment effect of MLC601 over 2 years.

Methods: The CHIMES-E study evaluated the 2 years outcome of subjects aged ≥ 18 years with acute ischemic stroke, National Institutes of Health Stroke Scale (NIHSS) score 6–14, pre-stroke modified Rankin Scale (mRS) score ≤ 1 included in a multicenter, randomized, double-blind, placebo-controlled trial of MLC601 for 3 months. Standard stroke care and rehabilitation were allowed during follow-up with mRS score being assessed in-person at month (M) 3 and by telephone at M1, M6, M12, M18 and M24.

Results: Data from 880 subjects were analyzed. There was no difference in baseline characteristics between treatment groups. The proportion of subjects with mRS score 0–1 increased over time in favor of MLC601 most notably from M3 to M6, thereafter remaining stable up to M24, while the proportion deteriorating to mRS score ≥ 2 remained low at all time points. Older age (p < 0.01), female sex (p = 0.06), higher baseline NIHSS score (p < 0.01) and longer onset to treatment time (OTT; p< 0.01) were found to be predictors of poorer outcome at M3. Greater treatment effect, with more subjects improving on MLC601 than placebo, was seen among subjects with 2 or more prognostic factors (OR 1.65 at M3, 1.78 at M6, 1.90 at M12, 1.65 at M18, 1.39 at M24), especially in subjects with more severe stroke or longer OTT.

Conclusions: The sustained benefits of MLC601 over 2 years were due to more subjects improving to functional independence at M6 and beyond compared to placebo. Selection of subjects with poorer prognosis, particularly those with more severe NIHSS score and longer OTT delay, as well as a long follow-up period, may improve the power of future trials investigating the treatment effect of neuroprotective or neurorestorative therapies.

 

Download the full paper

Moleac’s Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards

By News

NeuroAiDTM has been named New Product Innovation of the Year by Frost & Sullivan. This award recognizes healthcare products that are bringing innovative solutions for neurological disorders by pushing the boundaries of the usual practices. This award also acknowledges Moleac for its effort and continuous investment in NeuroAiDTM‘s Research and Development. Mr. David Picard, CEO of Moleac, received the 2016 Frost & Sullivan Asia Pacific New Product Innovation Award at the awards ceremony held this evening at Conrad Singapore. The ceremony was attended by leaders from the healthcare sector.

Frost & Sullivan followed a rigorous measurement-based methodology to select NeuroAiDTM as the recipient. Its independent panel of judges included senior members across various offices at Frost & Sullivan. The judging panel looked at market performance indicators, including revenue growth, market share, availabilities, geographical expansion and marketing strategies. The full  Frost & Sullivan Award Research Report for Moleac is available here.

Dr. M. Shaillender, Industry Analyst, Healthcare Practice – Asia Pacific at Frost & Sullivan, said, “Stroke rehabilitation is an underserved segment in the pharmaceutical industry. Moleac aims to address the existing gaps in stroke therapy with an unconventional approach similar to reverse innovation.’ NeuroAiDTM is a product originating from Traditional Chinese Medicine that has demonstrated excellent attributes in post-stroke recovery, however, without any scientific and clinical evidence. Moleac’s team was instrumental in identifying and decoding the underlying neuromodulatory properties to translate it into a therapeutic drug supported by clinical evidence for neurological disorders.”

He further adds, “As one of the first therapies of its kind, NeuroAiDTM is today accepted as an innovative treatment for post-stroke recovery. It is approved and marketed in over 35 countries as a supplement for stroke rehabilitation. Executing well in its vision, Moleac is on a trajectory to expand the horizons of NeuroAiDTM into a mainstream therapeutic drug for neurological disorders.”

David Picard, CEO of Moleac, said, “I am delighted to receive this award from Frost & Sullivan while we are celebrating the 10 years’ anniversary of NeuroAiDTM. Having launched NeuroAiDTM in 2006, we have been focusing our efforts on making NeuroAiDTM available to stroke sufferers around the world. NeuroAiDTM is the first medicine to support stroke recovery, and this is a huge unserved need for millions of suffers. In 2016, over 20,000 patients benefited from NeuroAiDTM worldwide and we aim at making NeuroAiDTM available to more patients in the coming years.”

He continued to add, “I would like to thank all those who have contributed to NeuroAiDTM‘s development over the past 10 years. This includes our academic partners, who have shown interest in our approach enabling its clinical development, our investors who have trusted us, and of course my colleagues who have made this venture a success. Without their support, NeuroAiDTM would not be where it is today. We keep investing in Research with several on-going clinical studies to provide first-class evidences of NeuroAiDTM‘s benefits in other unserved neurological disorders.”

NeuroAiDTM is a natural medicine originating from Traditional Chinese Medicine. In addition to its excellent safety profile, clinical trials have shown that patients taking NeuroAiDTM for 3 months have higher chances to reach functional recovery, with prolonged benefits over the long-term as published in Cerebrovascular Diseases (April 2015). About 3,000 subjects have been included in clinical trials and Moleac is currently supporting additional international clinical trials to demonstrate the potential of NeuroAiDTM in other neurological disorders.

About Moleac: Moleac is a Singapore-based biopharmaceutical company that dedicates itself to finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiDTM: NeuroAiDTM is a post-stroke recovery treatment to help stroke survivors achieve a faster and better recovery. Moleac also markets NeuroAiD II, a simplified formula. Both products are shown to be equivalent in pharmacology. It currently reaches out to patients in over 35 countries.

chimes society

NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset

By News

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases1 . It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients’ recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 17- 19, as part of the Scientific Program during the Clinical Trial session.

The CHIMES-E study is a planned, international and multicenter study performed in a blinded and placebo-controlled manner. It has included 880 patients from the CHIMES study who have suffered an ischemic stroke of intermediate severity within 72 hours, treated with NeuroAiD™ or placebo for 3 months after the initial stroke. The main purpose of this study was to evaluate the effects of an initial 3-month course with NeuroAiD™ on long-term outcomes for up to 2 years.

This study has showed that NeuroAiD™ increases significantly the odds of achieving functional independence at 6 months which persisted up to 18 months after stroke, as measured by the mRS. All these results were consistent at various time points and seen on 2 indices, i.e. mRS and BI. It also provided further long-term safety data on NeuroAiD™, even when combined with other stroke treatments. “These persistent benefits seen up to 18 months are a clinical confirmation of the previously established neurorestorative properties (i.e. neuroplasticity and neurogenesis) of NeuroAiD™, and suggest that it may be beneficial to extend NeuroAiD™ treatment beyond the first 3 months after stroke,” said Prof. Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study. “The CHIMES-E study provides new insight on the need for long-term assessment of post-stroke recovery in clinical trials of agents with neuroprotective and neurestorative properties such as NeuroAiD.

These results confirm the hypothesis raised by the CHIMES investigators: longer treatment duration and follow-up beyond 3 months of stroke patients is needed to assess stroke recovery2

About CHIMES Society

The CHIMES Society is an international academic industry collaboration with the objective to establish new stroke treatments. It is a Singaporean non-profit society founded by a group of experts in stroke and South-East Asian stroke clinicians interested to implement a research project: the NeuroAiD™ Efficacy on stroke recovery trial (CHIMES trial).

The CHIMES-E Study was supported by the CHIMES society and grants were received by CHLC from the National Medical Research Council in Singapore (NMRC) which supports the implementation of CHIMES trial in Singapore.

About Moleac

To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from Natural Medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers’ unaddressed needs. Moleac’s neurorestorative compound NeuroAiD™ reaches patients in more than 30 countries.

For more information,

contact: news@chimes-society.org

1- Venketasubramanian N, et al. CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy. Cerebrovascular Diseases 2015;44 39:309–318.

2- Venketasubramanian N, et al. Chinese medicine NeuroAiD efficacy stroke recovery-extension study (CHIMES-E study): an observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery. Cerebrovasc Dis 2013; 35(suppl 1):18–22.